GENSIGHT BIOLOGICS: Nature publication highlights light at the end of the tunnel in RP | BUY | EUR18(+118%)
GENSIGHT BIOLOGICS - BUY | EUR18(+118%)Nature publication highlights light at the end of the tunnel in RP
Landmark result from first publication of optogenetic data
Initial signs a breakthrough for driving further value from GS030
GS030 could become main value driver for GenSight story
TP EUR 18, keep BUY, GS030 EUR 4 per share
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.